CIPROXIN 250 MG FILM-COATED TABLETS 250 Base Milligrams Film Coated Tablet

Country: Ireland

Language: English

Source: HPRA (Health Products Regulatory Authority)

Buy It Now

Active ingredient:

CIPROFLOXACIN HYDROCHLORIDE

Available from:

PCO Manufacturing

INN (International Name):

CIPROFLOXACIN HYDROCHLORIDE

Dosage:

250 Base Milligrams

Pharmaceutical form:

Film Coated Tablet

Authorization status:

Withdrawn

Authorization date:

0000-00-00

Summary of Product characteristics

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Ciproxin 250 mg Film-coated Tablets.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 250 mg ciprofloxacin (as hydrochloride).
For full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Film-coated tablet.
_Product imported from Hungary:_
White, round tablets with Bayer cross impressed on one side and ‘CIP’, a breakline and ‘250’ impressed on the other.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Ciprofloxacin is indicated for the treatment of the following infections caused by sensitive bacteria:
_Adults:_
Respiratory tract infections: e.g. lobar and bronchopneumonia, acute and chronic bronchitis, acute exacerbation of
cystic fibrosis, bronchiectasis, empysema. Ciprofloxacin is not recommended as first-line therapy for the treatment of
pneumococcal pneumonia. In circumstances where a physician considers it appropriate to use ciprofloxacin in patients
with pneumococcal pneumonia, a dose of 750mg twice daily should provide adequate cover in the majority of cases
_(see Dosage and Administration section). _Ciprofloxacin may be used for treating Gram-negative pneumonia.
_Urinary tract infections:_e.g. uncomplicated and complicated urethritis, cystitis, pyelonephritis, prostatitis, epididymitis.
_Gastro-intestinal infections: _e.g. enteric fever, infective diarrhoea.
_Gonorrhoea: _including urethral, rectal and pharyngeal gonorrhoea caused by ß-lactamase producing organisms or
organisms moderately sensitive to penicillin.
_Children:_
For the treatment of acute pulmonary exacerbation of cystic fibrosis associated with P. aeruginosa infection in
paediatric patients aged 5-17 years.
Inhalation Anthrax in Adults and Children: to reduced the incidence or progression of disease following confirmed or
suspected ex
                                
                                Read the complete document